In one paragraphArticle in Science translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
19 authors.
Xiaofan LiHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0003-4168-0068 Zoë Weaver OhlerCenter for Advanced Preclinical Research, Center for Cancer Research, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.ORCID 0000-0002-6287-2504 Amanda DayCenter for Advanced Preclinical Research, Center for Cancer Research, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.ORCID 0000-0002-4456-8883 Laura BasselCenter for Advanced Preclinical Research, Center for Cancer Research, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.ORCID 0000-0003-1684-6839 Anna K GrosskopfHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0001-5814-1349 Bahman AfsariHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0001-8717-7199 Takanobu TagawaHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0001-8637-2996 Wendi CusterCenter for Advanced Preclinical Research, Center for Cancer Research, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.ORCID 0009-0009-0781-1213 Donna ButcherMolecular Histopathology Laboratory, Laboratory Animal Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.ORCID 0000-0002-2065-8067 Ralph MangusanHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Sukhbir KaurHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0003-0513-6225 Edmund CauleyAdvanced Biomedical Computational Sciences, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21701, USA.ORCID 0000-0002-8968-6621 Maria HernandezSpatial Imaging Technology Resources, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0009-0003-5114-5584 Noemi KedeiSpatial Imaging Technology Resources, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Kathryn LurainHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0002-5794-7292 Robert YarchoanHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0002-3057-1395 Joseph ZiegelbauerHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0001-6464-6941 Ramya RamaswamiHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0001-5709-4675 Laurie T KrugHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0002-9648-522X Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MClinical Trials of Patients with AIDS-Related MalignanciesZIABC010888 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI YARCHOAN, ROBERT · 2009 to 2025
$20.6MInvestigation of viral and host determinants of gammaherpesvirus pathogenesisZIABC011953 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KRUG, LAURIE TATE · 2020 to 2025
$8.1MIntramural NIH HHS ZIA BC010888Intramural NIH HHS ZIA BC011953NIH HHS 75N91019D00024
6 · The paper itselfAbstract
Kaposi sarcoma (KS) is defined by aberrant angiogenesis driven by Kaposi sarcoma herpesvirus (KSHV)-infected spindle cells with endothelial characteristics. KS research is hindered by rapid loss of KSHV infection upon explant culture of tumor cells. Here, we established KS patient-derived xenografts (PDXs) through orthotopic implantation of cutaneous KS biopsies into immunodeficient mice. KS tumors were maintained in 27 of 28 PDXs until the experimental end point. KSHV latency-associated nuclear antigen-positive (LANA
Indexed as
AngiogenesisEndothelial CellsHerpesvirus 8, HumanNeovascularization, PathologicReceptors, CXCR4Sarcoma, KaposiUp-RegulationAnimalsAntigens, ViralCell ProliferationChemokine CXCL12Disease Models, AnimalHumansMiceNuclear ProteinsAntigens, ViralChemokine CXCL12latency-associated nuclear antigenNuclear ProteinsReceptors, CXCR4
Identifiers
PMID42384773
PMCPMC13366591
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390